Belite Bio, Inc (NASDAQ:BLTE)
| Market Cap | 5.93B+57.0% |
| Revenue (ttm) | 0 |
| Net Income | -102.36M-107.3% |
| EPS | -2.76-79.2% |
| Shares Out | 40.27M |
| PE Ratio | n/a |
| Forward PE | 77.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,853 |
| Open | 151.20 |
| Previous Close | 150.27 |
| Day's Range | 146.30 - 151.20 |
| 52-Week Range | 90.77 - 200.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 245.83(+66.86%) |
| Earnings Date | Nov 9, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About BLTE
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BLTE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BLTE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BLTE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BLTE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BLTE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BLTE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BLTE
| ETF | Est. Holding Size |
|---|---|
| SPEMState Street SPDR Portfolio Emerging Markets ETF | $4.49M |
| APIEActivePassive International Equity ETF | $632.04K |
| ONEQFidelity Nasdaq Composite Index ETF | $565.62K |
| GXCState Street SPDR S&P China ETF | $479.66K |
| BBCVirtus Biotech Clinical Trials ETF | $345.17K |
| EHLSEven Herd Long Short ETF | $193.40K |
Estimated from each fund’s disclosed top holdings × AUM
BLTE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BLTE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score